NASDAQ:BLPH Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis → Time is Running Out - June 25th Deadline Approaching! (From Paradigm Press) (Ad) Free BLPH Stock Alerts $0.07 +0.02 (+36.43%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$0.06▼$0.0750-Day Range$0.05▼$0.0652-Week Range$0.03▼$0.80Volume6,345 shsAverage Volume47,838 shsMarket Capitalization$916,027.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsSustainabilityTrends Get Bellerophon Therapeutics alerts: Email Address Ad Paradigm PressMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.This Crypto bull market is not even halfway over About Bellerophon Therapeutics Stock (NASDAQ:BLPH)Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Read More BLPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLPH Stock News HeadlinesJune 2, 2024 | americanbankingnews.comBellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.comFebruary 25, 2024 | uk.finance.yahoo.comBellerophon Therapeutics, Inc. (BLPH)February 15, 2024 | investing.comBellerophon Therapeutics Inc (BLPH)January 31, 2024 | msn.comBellerophon Offers Series A Stock in Private SaleNovember 28, 2023 | benzinga.comHilco Streambank Seeks Offers to Acquire Patent Portfolio and Material Inventory of Biotherapeutics Company BellerophonNovember 2, 2023 | morningstar.comBellerophon Therapeutics Inc BLPHAugust 8, 2023 | finance.yahoo.comBLPH - Bellerophon Therapeutics, Inc.July 25, 2023 | msn.comWhat's Happening With Bellerophon Therapeutics Stock Today?July 25, 2023 | investorplace.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today?July 6, 2023 | msn.comBellerophon Therapeutics (BLPH) Price Target Decreased by 92.23% to 2.04June 6, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Bellerophon TherapeuticsJune 6, 2023 | finance.yahoo.comIs Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year?June 6, 2023 | msn.comLaidlaw & Co. Downgrades Bellerophon Therapeutics (BLPH)June 6, 2023 | msn.comHC Wainwright & Co. Maintains Bellerophon Therapeutics (BLPH) Buy RecommendationJune 5, 2023 | msn.comBellerophon Therapeutics Stock Nosedive: Here's WhyJune 5, 2023 | msn.comWhy Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today?June 5, 2023 | finance.yahoo.comBellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung DiseaseMay 19, 2023 | msn.comLucy Scientific, Bioventus top healthcare gainers; Enveric, Elevation among losersMay 17, 2023 | finance.yahoo.comBellerophon Therapeutics (NASDAQ:BLPH) delivers shareholders fantastic 978% return over 1 year, surging 18% in the last week aloneMay 16, 2023 | finanznachrichten.deBellerophon Therapeutics, Inc.: Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 15, 2023 | finance.yahoo.comBellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial ResultsMay 11, 2023 | finance.yahoo.comBellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung DiseaseApril 28, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Outpaces Stock Market Gains: What You Should KnowApril 24, 2023 | finance.yahoo.comBellerophon (BLPH) to Report Q1 Earnings: What's in the Cards?April 19, 2023 | finance.yahoo.comBellerophon Therapeutics (BLPH) Dips More Than Broader Markets: What You Should KnowSee More Headlines Receive BLPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today6/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BLPH CUSIPN/A CIK1600132 Webwww.bellerophon.com Phone(908) 574-4770FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,830,000.00 Net MarginsN/A Pretax Margin-186.70% Return on Equity-187.35% Return on Assets-104.97% Debt Debt-to-Equity RatioN/A Current Ratio3.96 Quick Ratio3.96 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book0.28Miscellaneous Outstanding Shares12,230,000Free Float11,597,000Market Cap$916,027.00 OptionableNo Data Beta0.71 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Craig R. Jalbert CIRA (Age 62)President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director Key CompetitorsPaxMedicaNASDAQ:PXMDAridis PharmaceuticalsNASDAQ:ARDSAgile TherapeuticsNASDAQ:AGRXBiophytisNASDAQ:BPTSYSeelos TherapeuticsNASDAQ:SEELView All CompetitorsInsidersPuissance Capital Management LSold 1,076,841 sharesTotal: $107,684.10 ($0.10/share)View All Insider Transactions BLPH Stock Analysis - Frequently Asked Questions How have BLPH shares performed in 2024? Bellerophon Therapeutics' stock was trading at $0.0370 at the beginning of 2024. Since then, BLPH shares have increased by 102.4% and is now trading at $0.0749. View the best growth stocks for 2024 here. How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) posted its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter. When did Bellerophon Therapeutics' stock split? Bellerophon Therapeutics shares reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX). When did Bellerophon Therapeutics IPO? Bellerophon Therapeutics (BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. How do I buy shares of Bellerophon Therapeutics? Shares of BLPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLPH) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellerophon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellerophon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.